CA3241501A1 - Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 - Google Patents
Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2Info
- Publication number
- CA3241501A1 CA3241501A1 CA3241501A CA3241501A CA3241501A1 CA 3241501 A1 CA3241501 A1 CA 3241501A1 CA 3241501 A CA3241501 A CA 3241501A CA 3241501 A CA3241501 A CA 3241501A CA 3241501 A1 CA3241501 A1 CA 3241501A1
- Authority
- CA
- Canada
- Prior art keywords
- salt
- hyperglycaemia
- treatment
- diabetes
- tartrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2117828.0 | 2021-12-09 | ||
| GB2117828.0A GB2613616A (en) | 2021-12-09 | 2021-12-09 | New formulations |
| PCT/EP2022/085133 WO2023105035A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241501A1 true CA3241501A1 (en) | 2023-06-15 |
Family
ID=80079964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241501A Pending CA3241501A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250042856A1 (OSRAM) |
| EP (1) | EP4444699A1 (OSRAM) |
| JP (1) | JP2024544698A (OSRAM) |
| KR (1) | KR20240116482A (OSRAM) |
| CN (1) | CN118525004A (OSRAM) |
| AU (1) | AU2022405700A1 (OSRAM) |
| CA (1) | CA3241501A1 (OSRAM) |
| GB (1) | GB2613616A (OSRAM) |
| IL (1) | IL313292A (OSRAM) |
| MX (1) | MX2024006960A (OSRAM) |
| WO (1) | WO2023105035A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202303229D0 (en) * | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| BR112021018481A2 (pt) * | 2019-03-27 | 2021-11-23 | Curasen Therapeutics Inc | Agonista adrenérgico beta e métodos para usar o mesmo |
-
2021
- 2021-12-09 GB GB2117828.0A patent/GB2613616A/en active Pending
-
2022
- 2022-12-09 US US18/717,134 patent/US20250042856A1/en active Pending
- 2022-12-09 MX MX2024006960A patent/MX2024006960A/es unknown
- 2022-12-09 WO PCT/EP2022/085133 patent/WO2023105035A1/en not_active Ceased
- 2022-12-09 EP EP22835607.7A patent/EP4444699A1/en active Pending
- 2022-12-09 IL IL313292A patent/IL313292A/en unknown
- 2022-12-09 CN CN202280081693.4A patent/CN118525004A/zh active Pending
- 2022-12-09 AU AU2022405700A patent/AU2022405700A1/en active Pending
- 2022-12-09 KR KR1020247020161A patent/KR20240116482A/ko active Pending
- 2022-12-09 JP JP2024534196A patent/JP2024544698A/ja active Pending
- 2022-12-09 CA CA3241501A patent/CA3241501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118525004A (zh) | 2024-08-20 |
| GB202117828D0 (en) | 2022-01-26 |
| MX2024006960A (es) | 2024-06-24 |
| IL313292A (en) | 2024-08-01 |
| AU2022405700A1 (en) | 2024-06-20 |
| GB2613616A (en) | 2023-06-14 |
| EP4444699A1 (en) | 2024-10-16 |
| WO2023105035A1 (en) | 2023-06-15 |
| JP2024544698A (ja) | 2024-12-03 |
| KR20240116482A (ko) | 2024-07-29 |
| US20250042856A1 (en) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250042856A1 (en) | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 | |
| EP3681872B1 (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | |
| AU2023200999B2 (en) | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | |
| EP3681862B1 (en) | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | |
| US12378216B2 (en) | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | |
| US11793774B2 (en) | Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia | |
| CA3133768A1 (en) | Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia | |
| US20240010620A1 (en) | Arylazabicyclo[2.1.1]hexylmethanols derivatives and medical uses thereof | |
| WO2025186320A1 (en) | Combinations of beta 2-adrenergic receptor agonists and sglt2 inhibitors for use in treating hyperglycaemia or a disorder characterized by hyperglycaemia | |
| WO2024200777A1 (en) | Substituted hydroxymethyl pyrrolidines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia | |
| IL323111A (en) | Combination of beta-2-adrenergic receptor agonists and glp-1 receptor agonists for use in the treatment of hyperglycemia | |
| HK40033371A (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | |
| HK40033371B (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED Effective date: 20240702 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251125 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251125 |